Alpha Tau Medical (NASDAQ:DRTS) Shares Up 2.1% - What's Next?

Key Points

• Alpha Tau Medical's stock price increased by 2.1% on Thursday, trading as high as $3.93 before closing at $3.83 with a volume increase of 74% from the average.
• HC Wainwright reaffirmed a "buy" rating with a price target of $9.00 for Alpha Tau Medical, which currently holds an average rating of "Buy" among analysts.
• The company reported a loss of ($0.13) earnings per share in its recent quarterly earnings, below analysts' expectations of ($0.12).

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report)'s stock price rose 2.1% during trading on Thursday . The company traded as high as $3.93 and last traded at $3.83. Approximately 108,494 shares were traded during trading, an increase of 74% from the average daily volume of 62,361 shares. The stock had previously closed at $3.75.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price objective on shares of Alpha Tau Medical in a report on Wednesday, September 3rd. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $9.00.

Alpha Tau Medical Stock Down 0.5%

The stock has a market capitalization of $325.71 million, a P/E ratio of -8.00 and a beta of 1.00. The firm's fifty day moving average is $3.30 and its 200-day moving average is $2.98. The company has a current ratio of 10.52, a quick ratio of 5.81 and a debt-to-equity ratio of 0.07.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities research analysts predict that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Alpha Tau Medical

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of Alpha Tau Medical in the first quarter worth about $53,000. Northern Trust Corp raised its stake in shares of Alpha Tau Medical by 112.6% in the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after acquiring an additional 25,770 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC raised its stake in shares of Alpha Tau Medical by 601.4% in the first quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock worth $568,000 after acquiring an additional 194,055 shares during the last quarter. 2.65% of the stock is owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.